Frontiers in pharmacology · 2026
Reserpine-induced fibromyalgia model in female rats is a long-lasting painful condition masked by antinociceptive endogenous opioids.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Juárez-Núñez Cristina, Segura-Chama Pedro, Pizaña-Encarnación Juan Miguel, Pellicer Francisco, Granados-Soto Vinicio, Mercado Francisco, Almanza Angélica
Аннотация
BACKGROUND: Fibromyalgia (FM) is a chronic painful condition that primarily affects women. The allodynia and hyperalgesia induced by reserpine is a FM model commonly used to study the disease; however, it produces one painful episode, in contrast to FM, which is a chronic painful condition. Reserpine induces hypersensitivity for 10 days, which is resolved by day-21. In this study, we sought to determine whether the resolution of pain was due to the release of endogenous antinociceptive opioids and the activation of spinal opioid receptors.
METHODS: Female Wistar rats were used in this study. To induce a fibromyalgia-like model, reserpine was subcutaneously administered. Twenty-one days after reserpine administration, subcutaneous or intrathecal opioid blockers were administered to evaluate latent sensitization. Additionally, serum β-endorphin concentration was determined by ELISA.
RESULTS: Reserpine produced transitory hyperalgesia and allodynia, which was resolved by day 21. Systemic administration of naloxone on days 21, 33, and 45 reinstated hypersensitivity. Likewise, intrathecal administration of naltrexone or specific antagonists of μ and δ opioid receptors (CTOP and naltrindole) reinstated hypersensitivity. These results suggest that an increased concentration of opioid agonists in reserpinized animals leads to antinociceptive effects. Accordingly, reserpine injection enhanced serum β-endorphin concentration in female rats.
CONCLUSION: Our data suggest that reserpine-induced nociceptive hypersensitivity is a long-lasting condition masked by the compensatory release of β-endorphin and the activation of spinal µ and, to a lesser extent, δ opioid receptors.
METHODS: Female Wistar rats were used in this study. To induce a fibromyalgia-like model, reserpine was subcutaneously administered. Twenty-one days after reserpine administration, subcutaneous or intrathecal opioid blockers were administered to evaluate latent sensitization. Additionally, serum β-endorphin concentration was determined by ELISA.
RESULTS: Reserpine produced transitory hyperalgesia and allodynia, which was resolved by day 21. Systemic administration of naloxone on days 21, 33, and 45 reinstated hypersensitivity. Likewise, intrathecal administration of naltrexone or specific antagonists of μ and δ opioid receptors (CTOP and naltrindole) reinstated hypersensitivity. These results suggest that an increased concentration of opioid agonists in reserpinized animals leads to antinociceptive effects. Accordingly, reserpine injection enhanced serum β-endorphin concentration in female rats.
CONCLUSION: Our data suggest that reserpine-induced nociceptive hypersensitivity is a long-lasting condition masked by the compensatory release of β-endorphin and the activation of spinal µ and, to a lesser extent, δ opioid receptors.